Mutual Advisors LLC grew its position in ResMed Inc. (NYSE:RMD - Free Report) by 196.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,595 shares of the medical equipment provider's stock after purchasing an additional 1,719 shares during the quarter. Mutual Advisors LLC's holdings in ResMed were worth $612,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of RMD. GAMMA Investing LLC increased its holdings in shares of ResMed by 23,982.6% during the 1st quarter. GAMMA Investing LLC now owns 733,556 shares of the medical equipment provider's stock worth $164,207,000 after purchasing an additional 730,510 shares during the period. Invesco Ltd. grew its position in ResMed by 32.2% during the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock worth $531,706,000 after buying an additional 566,046 shares in the last quarter. Norges Bank bought a new position in ResMed during the fourth quarter valued at about $118,605,000. Captrust Financial Advisors raised its holdings in ResMed by 813.4% in the 4th quarter. Captrust Financial Advisors now owns 443,340 shares of the medical equipment provider's stock valued at $101,387,000 after acquiring an additional 394,803 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in ResMed by 133.6% in the 4th quarter. AQR Capital Management LLC now owns 625,054 shares of the medical equipment provider's stock valued at $142,944,000 after acquiring an additional 357,466 shares in the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.
Insiders Place Their Bets
In related news, Director Witte Jan De sold 2,000 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $243.47, for a total value of $486,940.00. Following the completion of the sale, the director owned 5,806 shares in the company, valued at $1,413,586.82. This represents a 25.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Peter C. Farrell sold 945 shares of the business's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $255.49, for a total value of $241,438.05. Following the completion of the transaction, the director directly owned 68,273 shares of the company's stock, valued at approximately $17,443,068.77. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,013 shares of company stock worth $7,238,913. Company insiders own 0.71% of the company's stock.
ResMed Trading Down 1.3%
Shares of NYSE:RMD traded down $3.37 during midday trading on Wednesday, hitting $253.23. The company had a trading volume of 228,463 shares, compared to its average volume of 966,574. The company has a current ratio of 3.41, a quick ratio of 2.49 and a debt-to-equity ratio of 0.12. ResMed Inc. has a 12 month low of $188.56 and a 12 month high of $263.05. The firm has a fifty day simple moving average of $249.26 and a 200 day simple moving average of $236.25. The stock has a market cap of $37.13 billion, a price-to-earnings ratio of 28.42, a PEG ratio of 1.61 and a beta of 0.77.
ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. ResMed had a return on equity of 25.67% and a net margin of 26.15%. The company had revenue of $1.29 billion during the quarter, compared to analysts' expectations of $1.28 billion. During the same period in the prior year, the business posted $2.13 EPS. ResMed's revenue was up 7.9% on a year-over-year basis. On average, analysts predict that ResMed Inc. will post 9.47 EPS for the current year.
ResMed Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, June 12th. Shareholders of record on Thursday, May 8th were issued a $0.53 dividend. The ex-dividend date of this dividend was Thursday, May 8th. This represents a $2.12 annualized dividend and a yield of 0.84%. ResMed's dividend payout ratio (DPR) is presently 23.79%.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on RMD shares. Morgan Stanley set a $286.00 price objective on ResMed and gave the stock an "overweight" rating in a report on Tuesday, May 20th. Piper Sandler cut their price target on shares of ResMed from $260.00 to $248.00 and set a "neutral" rating for the company in a report on Thursday, April 24th. JPMorgan Chase & Co. boosted their price objective on ResMed from $286.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, April 24th. Wall Street Zen lowered shares of ResMed from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Mizuho set a $265.00 price target on shares of ResMed in a report on Wednesday, April 16th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $259.33.
Get Our Latest Research Report on RMD
About ResMed
(
Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Featured Stories

Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report